In August of 2017, this Multi-District Litigation (“MDL”) was assigned to the Honorable Claire Cecchi in the District Court of New Jersey. As of August of 2023, there were approximately 12,500 cases pending in the MDL, making the PPI (proton-pump inhibitor) MDL the 5th largest in the country. The crux of these claims involve the failure of the defendant-manufacturer pharmaceutical companies to warn patients and healthcare providers about the risk of serious kidney injury associated with their respective PPI products.
In October 2023, defendant, AstraZeneca Pharmaceuticals agreed to pay $425 million to settle approximately 11,000 lawsuits filed against them by individuals who alleged they suffered both acute and chronic kidney injuries after ingesting Nexium and Prilosec. Prior to the AstraZeneca settlement, three other big-pharma defendants, including GlaxoSmithKline, Pfizer and Procter and Gamble, reached settlements totaling $108.5 million for their respective products.
As of April 2024, two defendant pharmaceutical companies have not settled the cases against them – Takeda Pharmaceuticals and Abbott Laboratories, manufacturers of Prevacid and Dexilant. The first case against these defendants is currently scheduled for trial in October 2024. We stand ready to proceed to trial this October and hold these two pharmaceutical companies accountable for their persistent failure to warn the public and consumers about the dangers associated with these PPI products.
Anapol Weiss is a renowned national leader in Mass Tort Litigation. Tracy Finken Magnotta, a shareholder at Anapol Weiss, is a staunch advocate for PPI victims and a member of the Plaintiffs’ Executive Committee for this MDL. Together, Tracy Finken Magnotta and Pamela Playo Lin, a newly minted partner with firm, represent hundreds of clients in this litigation.
“We are committed to our clients, and we are confident that justice will prevail here.” Learn more about PPI cases here: https://www.anapolweiss.com/practices/mass-torts/ppi/.